TP53
anthracyclines
biomarker
prognosis
sarcoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
05 Jul 2021
05 Jul 2021
Historique:
received:
08
06
2021
revised:
23
06
2021
accepted:
02
07
2021
entrez:
20
7
2021
pubmed:
21
7
2021
medline:
21
7
2021
Statut:
epublish
Résumé
(1) Background: locally resected high-grade sarcomas relapse in 40% of cases. There is no prognostic or predictive genomic marker for response to peri-operative chemotherapy. (2) Methods: MOSCATO and ProfiLER are pan-tumor prospective precision medicine trials for advanced tumors. Molecular analysis in both trials comprised targeted next-generation sequencing and comparative genomic hybridization array. We investigated if molecular alterations identified in these trials in sarcomas were associated with disease-free survival (DFS) and response to anthracyclines. (3) Results: this analysis included 215 sarcomas, amongst which 53 leiomyosarcomas, 27 rhabdomyosarcomas, 20 undifferentiated pleomorphic sarcomas, and 17 liposarcomas. The most frequently altered gene was
Identifiants
pubmed: 34282771
pii: cancers13133362
doi: 10.3390/cancers13133362
pmc: PMC8268242
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JAMA. 2020 Apr 7;323(13):1266-1276
pubmed: 32259228
Ann Oncol. 2019 May 1;30(5):757-765
pubmed: 30865223
J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4
pubmed: 16106022
Oncotarget. 2015 May 20;6(14):12234-47
pubmed: 25906748
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv68-iv78
pubmed: 29846513
Int J Cancer. 2016 Jan 15;138(2):489-96
pubmed: 26238069
Nat Med. 2010 Jul;16(7):781-7
pubmed: 20581836
J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52
pubmed: 19815849
JCO Precis Oncol. 2019 Apr 25;3:
pubmed: 32914012
J Cancer Res Clin Oncol. 2019 Mar;145(3):625-636
pubmed: 30542790
PLoS One. 2012;7(6):e38808
pubmed: 22719951
Int J Cancer. 1984 Jan 15;33(1):37-42
pubmed: 6693192
Cancer Discov. 2017 Jun;7(6):586-595
pubmed: 28365644
Int J Cancer. 2009 Feb 15;124(4):991-7
pubmed: 19048622
Cancer Cell. 2012 Jun 12;21(6):793-806
pubmed: 22698404
Ann Oncol. 2015 May;26(5):1012-1018
pubmed: 25669829
Lancet Oncol. 2017 Jun;18(6):812-822
pubmed: 28499583
Cancers (Basel). 2020 Dec 12;12(12):
pubmed: 33322802
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269
pubmed: 30285214
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Lancet Oncol. 2016 Apr;17(4):532-538
pubmed: 26970672
Nat Rev Clin Oncol. 2018 Jul;15(7):443-458
pubmed: 29666441
Ann Oncol. 2016 Mar;27(3):539-43
pubmed: 26646755
Ann Oncol. 2019 Jul 1;30(7):1143-1153
pubmed: 31081028
Ann Oncol. 2017 Nov 01;28(11):2852-2859
pubmed: 29117335
JCO Precis Oncol. 2018 Nov;2:1-8
pubmed: 35135155
Cell. 2017 Nov 2;171(4):950-965.e28
pubmed: 29100075
JAMA Oncol. 2018 Oct 1;4(10):1398-1404
pubmed: 29801054
Ann Oncol. 2014 Dec;25(12):2425-2432
pubmed: 25294887
Eur J Cancer. 2011 Jun;47(9):1319-27
pubmed: 21450455
Pharmacol Ther. 2019 Oct;202:149-164
pubmed: 31276706
Cancer Discov. 2014 Apr;4(4):405-14
pubmed: 24658082
Cell. 2009 Dec 24;139(7):1327-41
pubmed: 20064378
Cancer. 1994 May 15;73(10):2499-505
pubmed: 8174045
Oncotarget. 2017 Jun 13;8(24):39254-39267
pubmed: 28424409
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Cancer Immunol Res. 2021 Feb;9(2):170-183
pubmed: 33303573
PLoS One. 2012;7(6):e39655
pubmed: 22768103
Cancer Discov. 2014 Nov;4(11):1342-53
pubmed: 25223734
Breast Cancer Res. 2012 May 02;14(3):R70
pubmed: 22551440